OncoResponse

Executive Summary

OncoResponse is a clinical-stage biotechnology company pioneering a novel approach to cancer immunotherapy by harnessing antibodies from 'Elite Responders'—patients who achieve exceptional responses to checkpoint inhibitors. The company's proprietary platform identifies authentic human antibodies that can convert immunologically 'cold' tumors into 'hot' ones, thereby making them responsive to treatment. Based in Seattle, OncoResponse focuses on developing biologics that target novel immune checkpoints or pathways, aiming to expand the benefits of immunotherapy to a broader patient population. With a strong scientific foundation and a unique discovery platform, the company addresses a critical unmet need in oncology: resistance to existing immunotherapies.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate enters Phase 1 clinical trial15% success
• 2026Announcement of strategic partnership with major pharma30% success
• Q2 2026Presentation of preclinical data at major oncology conference70% success